- Lorus Therapeutics Inc. announced that its Phase I clinical study, conducted at MSKCC and the MD Anderson Cancer Center, of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
- MSKCC’s Dr. Peter Bach was quoted in a Reuters article about a study that found that pediatricians-in-training are more likely to plan to go into primary care – rather than a specialty field – if they have lots of debt from college and medical school.
- MSKCC was featured in Health Magazine’s top 12 medical breakthroughs of 2012.